EGFR and cancer: Although the clinical significance of this pathway remains unclear, the EGF receptor (EGFR), a transmembrane glycoprotein belonging to the HER family of receptors, is recognized as a negative prognostic indicator [11], [12] and has shown clinical relevance as a molecular target of cancer therapies [13], [14].